Show simple item record

dc.contributor.authorGlina, Sidney
dc.contributor.authorToscano, Iderpol
dc.contributor.authorGomatzky, Celso [UNIFESP]
dc.contributor.authorGoes, Plinio Moreira de [UNIFESP]
dc.contributor.authorNardozza Junior, Archimedes
dc.contributor.authorClaro, Joaquim Francisco de Almeida [UNIFESP]
dc.contributor.authorPagani, Eduardo
dc.identifier.citationJournal of Sexual Medicine. Malden: Wiley-Blackwell Publishing, Inc, v. 6, n. 2, p. 553-557, 2009.
dc.description.abstractOral treatment with phosphodiesterase type 5 inhibitor (PDE5) is considered the first-line treatment for patients with erectile dysfunction (ED). Lodenafil carbonate (LC) is a novel PDE5.This is a phase II, prospective, randomized, double-blind, and placebo controlled clinical trial of LC.Efficacy end points were International Index of Sexual Function (IIEF) erectile domain, IIEF questions 3 and 4, and Sexual Encounter Profile (SEP) questions 2 and 3, before and after the use of LC or placebo.Seventy-two men older than 18 years, with ED for at least 6 months with stable sexual relationship were enrolled. Patients were randomized to placebo or LC 80 mg, 40 mg, or 20 mg and followed for 4 weeks.IIEF erectile domain scores before and after the use of medications were (mean +/- standard deviation [SD]): placebo: 11.9 +/- 3.4 and 12.6 +/- 5.5; LC 20 mg: 15.8 +/- 4.1 and 18.9 +/- 6.6; LC 40 mg: 11.9 +/- 4.4 and 15.4 +/- 8.1; LC 80 mg: 14.2 +/- 4.7 and 22.8 +/- 6.0 (anova P < 0.01). the SEP-2 scores before and after the use of medications were (Mean +/- SD): placebo: 71.0 +/- 33.1 and 51.2 +/- 43.1; LC 20 mg 70.3 +/- 34.2 and 75.5 +/- 31.5; LC 40 mg: 48.4 +/- 42.1 and 60.8 +/- 42.5; LC 80 mg: 68.6 +/- 33.5 and 89.6 +/- 26.0. the SEP-3 scores were: placebo 23.3 +/- 27.6 and 33.6 +/- 42.3; LC 20 mg: 32.3 +/- 38.9 and 51.2 +/- 41.7; LC 40 mg: 39.7 +/- 44.7 and 46.7 +/- 41.1; LC 80 mg* 17.2 +/- 29.5 and 74.3 +/- 36.4 (*P < 0.05 for difference to placebo).The drug was well tolerated. Adverse reactions were mild and self-limited and included headache, rhinitis, flushing, color visual disorders, and dyspepsia. This study showed that the dosage of 80 mg of LC was significantly more efficacious than placebo and well tolerated. Glina S, Toscano I, Gomatzky C, de Goes PM, Junior AN, de Almeida Claro JF, and Pagani E. Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: A phase II clinical trial. J Sex Med 2009;6:553-557.en
dc.relation.ispartofJournal of Sexual Medicine
dc.rightsAcesso restrito
dc.subjectPhosphodiesterase Type 5 Inhibitor (PDE5)en
dc.subjectLodenafil Carbonateen
dc.subjectErectile Dysfunctionen
dc.titleEfficacy and Tolerability of Lodenafil Carbonate for Oral Therapy in Erectile Dysfunction: A Phase II Clinical Trialen
dc.contributor.institutionHosp Ipiranga
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionCristalia LTDA
dc.description.affiliationHosp Ipiranga, Inst H Ellis, BR-01333011 São Paulo, Brazil
dc.description.affiliationUniversidade Federal de São Paulo, Hosp São Paulo, São Paulo, Brazil
dc.description.affiliationUniv São Paulo, Hosp Clin, BR-05508 São Paulo, Brazil
dc.description.affiliationCristalia LTDA, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Hosp São Paulo, São Paulo, Brazil
dc.description.sourceWeb of Science

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record